SCLX
Scilex Holding Company
NASDAQ · USHealthcareDrug Manufacturers - General
$7.64-9.48%
Price as of Jul 20, 2026
SCLX financials
Scilex Holding Company financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $30.3M | $56.6M | $46.7M | $38.0M |
| Cost of revenue | $15.2M | $16.7M | $15.7M | $10.8M |
| Gross profit | $15.0M | $39.9M | $31.1M | $27.2M |
| Operating expenses | $287.3M | $123.3M | $136.5M | $77.9M |
| Operating income | -$272.3M | -$83.4M | -$105.4M | -$50.6M |
| Net income | -$358.7M | -$72.8M | -$114.3M | -$23.4M |
| EBITDA | -$357.9M | -$66.8M | -$109.1M | -$9.3M |
| Basic EPS | $-36.48 | $-19.43 | $-44.85 | $-6.09 |
| Diluted EPS | $-36.48 | $-19.43 | $-44.85 | $-6.09 |
| Balance sheet | ||||
| Cash & equivalents | $5.0M | $3.3M | $3.9M | $2.2M |
| Total assets | $365.0M | $93.0M | $101.3M | $86.5M |
| Total liabilities | $576.7M | $285.6M | $274.2M | $50.3M |
| Stockholders’ equity | -$207.8M | -$192.6M | -$172.9M | $36.2M |
| Total debt | $132.5M | $38.0M | $128.5M | $1.4M |
| Net debt | $127.6M | $34.7M | $124.5M | -$774.0K |
| Cash flow | ||||
| Operating cash flow | $3.8M | $19.3M | -$20.7M | -$21.3M |
| Capital expenditure | -$133.0K | -$600.0K | -$330.0K | -$2.1M |
| Free cash flow | $3.7M | $18.7M | -$21.0M | -$23.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | -$10.0M | $0.00 |